CN114728177B - 作为Kv1.3钾Shaker通道阻滞剂的芳基杂二环化合物 - Google Patents

作为Kv1.3钾Shaker通道阻滞剂的芳基杂二环化合物 Download PDF

Info

Publication number
CN114728177B
CN114728177B CN202080084476.1A CN202080084476A CN114728177B CN 114728177 B CN114728177 B CN 114728177B CN 202080084476 A CN202080084476 A CN 202080084476A CN 114728177 B CN114728177 B CN 114728177B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
alkyl
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080084476.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114728177A (zh
Inventor
F·焦尔达内托
M·O·詹森
V·乔吉尼
R·J·斯诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DE Shaw Research LLC
Original Assignee
DE Shaw Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DE Shaw Research LLC filed Critical DE Shaw Research LLC
Publication of CN114728177A publication Critical patent/CN114728177A/zh
Application granted granted Critical
Publication of CN114728177B publication Critical patent/CN114728177B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
CN202080084476.1A 2019-10-07 2020-10-06 作为Kv1.3钾Shaker通道阻滞剂的芳基杂二环化合物 Active CN114728177B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962911642P 2019-10-07 2019-10-07
US62/911642 2019-10-07
PCT/US2020/054348 WO2021071803A1 (en) 2019-10-07 2020-10-06 Aryl heterobicyclic compounds as kv1.3 potassium shaker channel blockers

Publications (2)

Publication Number Publication Date
CN114728177A CN114728177A (zh) 2022-07-08
CN114728177B true CN114728177B (zh) 2025-06-24

Family

ID=75436850

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080084476.1A Active CN114728177B (zh) 2019-10-07 2020-10-06 作为Kv1.3钾Shaker通道阻滞剂的芳基杂二环化合物

Country Status (11)

Country Link
US (1) US20230040182A1 (cg-RX-API-DMAC7.html)
EP (1) EP4041408A4 (cg-RX-API-DMAC7.html)
JP (1) JP7780439B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220079575A (cg-RX-API-DMAC7.html)
CN (1) CN114728177B (cg-RX-API-DMAC7.html)
AU (1) AU2020363354A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022006250A2 (cg-RX-API-DMAC7.html)
CA (1) CA3156981C (cg-RX-API-DMAC7.html)
IL (1) IL291867A (cg-RX-API-DMAC7.html)
MX (1) MX2022004144A (cg-RX-API-DMAC7.html)
WO (1) WO2021071803A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116782894A (zh) 2020-10-06 2023-09-19 D.E.肖研究有限责任公司 作为Kv1.3钾Shaker通道阻断剂的内酰胺化合物
CN114437070A (zh) * 2022-01-19 2022-05-06 广西-东盟食品检验检测中心 一种他达拉非新型衍生物的制备方法
JP2026513122A (ja) * 2022-10-28 2026-04-23 上海深勢唯思科技有限責任公司 芳香族複素環式Kv1.3阻害剤、その製造方法及び用途
WO2025029769A1 (en) 2023-07-31 2025-02-06 Eli Lilly And Company Solid forms of a kv1.3 potassium shaker channel blockers and method of using the same
WO2026021011A1 (zh) * 2024-07-26 2026-01-29 浙江海正药业股份有限公司 芳基三环类衍生物及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102333782A (zh) * 2008-12-12 2012-01-25 雅培卫生保健产品有限责任公司 作为Kv1.3钾通道阻断剂的螺氮杂环庚烷-噁唑烷酮
CN107548396A (zh) * 2015-03-13 2018-01-05 4Sc股份公司 Kv1.3抑制剂及其医学应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365615B1 (en) * 1999-07-21 2002-04-02 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6939968B2 (en) 2002-12-23 2005-09-06 Bristol-Myers Squibb Company Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
CN1856477A (zh) 2003-09-23 2006-11-01 默克公司 异喹啉钾通道抑制剂
CN100530013C (zh) * 2005-03-04 2009-08-19 松下电器产业株式会社 电子设备控制装置及其控制方法
US7538110B2 (en) * 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
US8124636B2 (en) * 2008-04-30 2012-02-28 Hoffmann-La Roche Inc. Imidazolidinone derivatives as 11B-HSD1 inhibitors
WO2011073273A1 (en) 2009-12-16 2011-06-23 Evotec Ag Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators
US20120065210A1 (en) * 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102333782A (zh) * 2008-12-12 2012-01-25 雅培卫生保健产品有限责任公司 作为Kv1.3钾通道阻断剂的螺氮杂环庚烷-噁唑烷酮
CN107548396A (zh) * 2015-03-13 2018-01-05 4Sc股份公司 Kv1.3抑制剂及其医学应用

Also Published As

Publication number Publication date
WO2021071803A1 (en) 2021-04-15
EP4041408A1 (en) 2022-08-17
US20230040182A1 (en) 2023-02-09
AU2020363354A1 (en) 2022-04-21
KR20220079575A (ko) 2022-06-13
BR112022006250A2 (pt) 2022-06-21
JP7780439B2 (ja) 2025-12-04
CN114728177A (zh) 2022-07-08
CA3156981A1 (en) 2021-04-15
MX2022004144A (es) 2022-06-14
JP2022550641A (ja) 2022-12-02
IL291867A (en) 2022-06-01
EP4041408A4 (en) 2023-10-18
CA3156981C (en) 2025-06-17

Similar Documents

Publication Publication Date Title
JP7697954B2 (ja) Kv1.3カリウムシェーカーチャネル遮断薬としてのアリールメチレン芳香族化合物
CN114828963B (zh) 作为Kv1.3钾SHAKER通道阻滞剂的芳基杂二环化合物
JP7780439B2 (ja) Kv1.3カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物
JP2025186255A (ja) Kv1.3カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物
KR20230082041A (ko) Kv1.3 칼륨 셰이커 채널 차단제로서의 락탐 화합물
JP7716494B2 (ja) Kv1.3カリウムシェーカーチャネル遮断剤としてのアリール複素環化合物
CN114727993B (zh) 作为Kv1.3钾SHAKER通道阻断剂的芳基亚甲基杂环化合物
EA046803B1 (ru) АРИЛЬНЫЕ ГЕТЕРОБИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК БЛОКАТОРЫ КАЛИЕВОГО КАНАЛА Kv1.3 ТИПА SHAKER

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant